Toll Free Survivor Line


Stage 4 Breast Cancer


Patients diagnosed with Stage 4 breast cancer have disease that has spread from the affected breast to one or more distant sites in the body. There have been some important advances resulting in the addition of many more treatment options for managing this disease. These include the now widespread use of taxane chemotherapy, the development of targeted therapies, and the development of more active hormonal therapy drugs.


The following is an overview for the treatment for metastatic breast cancer. The presence of hormone receptors in the breast cancer cells determines whether hormonal therapy is a treatment option. If the cancer does not have estrogen or progesterone receptors, the mainstay of treatment is chemotherapy. Treatment may also include surgery, radiation, targeted therapy, or a combination of these treatment techniques. Multi-modality treatment, which utilizes two or more treatment types, is increasingly recognized as an important approach for improving a patient’s chance of cure or prolonging survival. In some cases, participation in a clinical trial may provide the most promising treatment.

Each patient’s situation will influen

ce the treatment choices used. The information on this web-site is intended to help educate patients about treatment options and to create discussion and help with the decision-making process with your treatment team.


The topics covered include:


• Hormonal Therapy

• Chemotherapy

• Targeted Therapy

• Treating Bone Metastases

• Treating Liver Metastases

• Methods to Improve Treatment


Hormonal Therapy for Metastatic Breast Cancer


The growth of some breast cancer cells can be prevented or slowed by reducing the exposure to estrogen. This is the goal of hormonal therapy in the treatment for breast cancer.


Estrogen can cause some cancers to grow. The breasts, uterus, and other female organs are composed of cells that are stimulated to grow when exposed to estrogen. These cells contain estrogen receptors. Estrogen circulating in the blood binds to these receptors and stimulates growth-related activities in the cell. When cells that have estrogen receptors become cancerous, exposure to estrogen increases the cancer’s growth. Cancer cells that have estrogen receptors are referred to as estrogen receptor-positive (ER-positive) cancers.


Removal of the ovaries, the organ mainly responsible for producing estrogen in premenopausal women, is one effective approach to eliminating estrogen production and is commonly used in many countries. Another approach is to utilize drugs that can accomplish a similar effect without removing the ovaries. These drugs include tamoxifen as well as a newer class of drugs known as aromatase inhibitors.


Aromatase inhibitors work by inhibiting the formation of estrogen in the body. Aromatase is the enzyme (protein) that initiates the conversion of estrogen to its active form. Aromatase inhibitors work by inhibiting aromatase, thereby reducing the levels of active estrogen in the body. This is in contrast to tamoxifen, which works by blocking estrogen from entering a cell through direct binding to the cell’s estrogen receptors.


Currently, three aromatase inhibitors are approved for the treatment of postmenopausal women with breast cancer: Femara® (letrozole), Arimidex® (anastrozole), and Aromasin® (exemestane). Hormonal Therapy for Breast Cancer.


Chemotherapy Treatment of Metastatic Breast Cancer


Patients with breast cancer that does not have estrogen/progesterone receptors, those not responding to hormonal treatment, and individuals requiring symptomatic relief from progressive breast cancer may benefit from treatment with chemotherapy.


The type of chemotherapy that is selected depends on the goal of treatment. If the goal of treatment is to reduce symptoms and improve quality of life, it may be more desirable to select a chemotherapy treatment with minimal side effects. On the other hand, if the goal of treatment is to attempt to cure the cancer, treatment with more aggressive chemotherapy regimens or participation in clinical studies evaluating new treatment strategies may be more appropriate.


It is important to carefully consider the goals of treatment. One reason for this is that initial treatment of Stage IV breast cancer is typically more effective than retreating cancer that has recurred because cancer cells may become resistant to therapy. Patients who are interested in aggressive treatment and whose goal is cure may want to consider aggressive therapy or participation in a clinical study as their first or initial treatment.




In recent years, a class of chemotherapy drugs called the taxanes has been widely used in the treatment of breast cancer. Taxotere® (docetaxel) and Taxol® (paclitaxel) are both taxanes that, when used in combination or sequentially with other chemotherapy drugs, appear to have more anti-cancer activity than previous non-taxane chemotherapy for the treatment of metastatic breast cancer. The best schedule for administering taxanes is still being evaluated. Some research indicates that more frequent administration may be better than the standard schedule of every three weeks.


Results from a large clinical trial indicate that Taxotere produces higher anti-cancer response rates, progression-free survival, and overall survival compared to Taxol,


Abraxane (nanoparticle albumin-bound paclitaxel): A new technique for delivering anti-cancer drugs has been recently developed, called nanoparticle albumin-bound (nab) technology. Abraxane is a treatment that delivers the anti-cancer drug paclitaxel using nab technology. This technique utilizes albumin, the most abundant protein in the body, to deliver the paclitaxel directly to cancer cells.


In a clinical trial that directly compared of Abraxane to Taxol in the treatment of 454 patients with metastatic breast cancer, Abraxane doubled anti-cancer response rates and significantly prolonged time to disease progression with fewer side effects compared to Taxol.


Combination Chemotherapy Regimens


Combinations of two or more chemotherapy drugs are referred to as regimens (or cocktails). Regimens have been shown to kill more cancer cells than single chemotherapy drugs. This is because each type of drug interrupts cells from replicating at different points in their lifecycle. Since all cancer cells are not at the same phase of development at the same time, chemotherapy regimens may interrupt and kill more cancer cells.


The optimal schedule for administering regimens is still being evaluated. Administering chemotherapy drugs in sequence (one following another), rather than together as a combination, has shown promise.


Regimens that Include a Taxane


Current research indicates that the following taxane-containing regimens improve outcomes over either a single drug or a conventional regimen:


Doxorubicin and paclitaxel (AT): Two clinical trials have shown that patients who receive AT live longer, are cancer-free longer, or experience a longer period of time before their cancer progresses than those who receive the common chemotherapy treatment consisting of fluorouracil, doxorubicin, and cyclophosphamide (FAC)


TAC (Taxotere, doxorubicin, and cyclophosphamide): In an attempt to further improve treatment, a third drug has been added to the AT regimen and evaluated as initial treatment for patients with metastatic breast cancer.


Gemzar® (gemcitabine) and Taxol (GT): Results of a clinical trial indicate that Gemzar and Taxol improves survival over Taxol alone in the treatment of patients with metastatic breast cancer who have stopped responding to anthracycline treatment. In May of 2004, the FDA approved GT for initial treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy, unless anthracyclines were clinically contraindicated.


Targeted Therapy


Targeted therapies are anticancer drugs that interfere with specific pathways involved in cancer cell growth or survival. Some targeted therapies block growth signals from reaching cancer cells; others reduce the blood supply to cancer cells; and still others stimulate the immune system to recognize and attack the cancer cell. Depending on the specific “target,” targeted therapies may slow cancer cell growth or increase cancer cell death.


HER2-targeted therapy: Twenty to thirty percent of breast cancers overexpress (make too much of) a protein known as HER2. Overexpression of this protein leads to increased growth of cancer cells. Fortunately, the development of treatments that specifically target HER2-positive cells has improved outcomes among women with HER2-positive breast cancer.


• Herceptin® (trastuzumab): Herceptin is an agent that recognizes and binds to HER2-positive cells. The effects of Herceptin are thought to include decreased cell growth and increased cell death. Results from an important clinical trial indicate that adding Herceptin to chemotherapy improves survival for patients with advanced HER2-positive breast cancer.


Avastin® (bevacizumab): Avastin is a targeted therapy that blocks a protein known as vascular endothelial growth factor (VEGF). VEGF stimulates the growth of new blood vessels. Drugs that interfere with VEGF can slow or stop the growth of cancer cells, and also improve the delivery of chemotherapy to cancer cells by normalizing blood supply.


Among women with advanced, HER2-negative breast cancer who have not received prior treatment for metastatic disease, treatment with Avastin plus paclitaxel resulted in a longer time to cancer progression than treatment with paclitaxel alone. The addition of Avastin did not, however, significantly improve overall survival.


Management of Bone Metastases


Breast cancer cells that have spread to the bones are called bone metastases. Cancer can spread to the bones when individual cancer cells break off from the original tumor and travel in the circulatory or lymph system until they get lodged in a small vessel in a new area. The cell then grows into another tumor. Management of bone metastases may include a bisphosphonate drug.


Bisphosphonates: Bisphosphonates are a class of drugs that decrease the rate of bone destruction in patients with cancer. Clinical studies have demonstrated that bisphosphonates can significantly decrease the number of fractures occurring from cancer that has spread to the bone and reduce the pain associated with cancer involving the bone.


Possibilities to Improve Treatment


The development of more effective cancer treatments requires that new and innovative therapies be evaluated with cancer patients. Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. Future progress in the treatment of metastatic breast cancer will result from the continued evaluation of new treatments in clinical trials. Participation in a clinical trial may offer patients access to better treatments and advance the existing knowledge about treatment of this cancer. Patients who are interested in participating in a clinical trial should discuss the risks and benefits of clinical trials with their physician.


Targeted Therapy


Epidermal Growth Factor Receptor (EGFR) inhibitors: Epidermal growth factor receptors (EGFR) are small proteins that are found on the surface of all cells. EGFR binds exclusively to small proteins circulating in the blood called growth factors. The binding action between EGFR and growth factors stimulates biological processes within the cell to promote controlled cellular growth. However, in many cancer cells, EGFR is either abundantly overexpressed, or the EGFR biological processes that normally stimulate cell growth are constantly active, leading to the uncontrolled and excessive growth of the cancer cell. Several drugs that inhibit EGFR have been developed and are currently being evaluated in the treatment of breast cancer.


Tarceva (erlotinib) is an EGFR inhibitor that is approved for the treatment of advanced non-small cell lung cancer and is being evaluated in the treatment of other cancers, including advanced breast cancer.


Vaccines: One strategy for stimulating the immune system to attack cancer cells is the use of vaccines. Cancer cells often display certain small proteins and/or carbohydrates (antigens) on their surface that are not displayed by healthy cells. Vaccines are often comprised of these specific antigens, which can be taken directly from the patient’s cancer cells, other patient’s cells, or produced in a laboratory. If these antigens are injected into the patient, the immune system recognizes them as “foreign” and will attack the cancer cells displaying the antigens. Researchers are now evaluating various strategies to enhance the immune response against the injected antigens, including combining the patient’s own immune cells with the specific antigens in a laboratory prior to injection.


Advances in Hormonal Therapy


Researchers continue to evaluate ways to improve hormonal therapy for breast cancer by evaluating new agents or different ways to administer drugs that are already in use. Aromasin and Faslodex® (fulvestrant) are approved for treatment of women with metastatic breast cancer that has stopped responding to tamoxifen, but not as initial treatment. However, research now indicates that these two anti-estrogen agents appear to be superior to tamoxifen as initial treatment of metastatic disease. Anti-cancer responses were three times more prevalent among patients treated with Aromasin compared to patients treated with tamoxifen (41% versus 17%). Treatment with Faslodex also resulted in more anti-cancer responses than tamoxifen, and patients who received Faslodex experienced a longer time before their cancer progressed.


Clinical Trials: New anti-cancer therapies continue to be developed and evaluated in clinical trials. There are three phases of clinical trials before approval.  See our clinical trials section for more information.


Management of Liver Metastases


When breast cancer spreads to the liver, it doesn’t always cause symptoms. It may be picked up by liver function tests, which are blood tests that measure certain levels of enzymes and proteins in the blood. Abnormal levels can indicate liver disease or damage.


If liver metastasis causes symptoms, they can include:


• pain or discomfort in the mid-section

• fatigue and weakness

• weight loss/poor appetite

• fever

• bloating

• swelling in the legs

• a yellow tint to the skin or the whites of the eyes


In addition to liver function tests, doctors use imaging tests to diagnose liver metastases. These may include MRI (magnetic resonance imaging), CT scan (computed tomography), ultrasound, and/or PET scan (positron emission tomography). Sometimes, a combined PET/CT scan is used.


Your doctor also may recommend getting a sample of the suspicious area(s) for examination under a microscope (biopsy). He or she may involve an interventional radiologist to obtain precise and minimally invasive imaging.


The most common treatments for metastatic breast cancer in any location (bone, brain, lung, or liver) are systemic medications, which treat cancer throughout the entire body. Systemic medications include chemotherapy, hormonal therapy, and targeted therapies that have already been discussed.  Liver directed therapies, including surgery, may be an option.


Liver Directed Therapies:  There are numerous liver directed therapies available for those who are faced with a Stage 4 Breast Cancer diagnosis with liver metastases or breast cancer that has spread to the liver.  These therapies are dependent on the size, number, and location of the liver tumors. These liver directed therapies may include chemoembolization, cryoablation, cyberknife, hepatic arterial infusion, liver resection, proton beam therapy, radioembolization or SIRT, radiofrequency ablation, or SBRT.  You can learn more on our treatment page under liver directed therapies.










Toll Free Survivor Line



Survivor Hotline: 1-877-937-7478 (US only);

The information presented in this Website is not intended as a substitute for medical care. Please talk with your healthcare provider about any information you get from this Website.

Thank you to Amgen, Bristol-Meyers Squibb,Eisai, Genentech, Lilly, Sirtex,Taiho and Wako,

 for your support in 2020